Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis with trial sequential analysis of randomized controlled trials

Critical Care

Volumn 20, Issue 1, 2016, Pages

  Liu, Chao ^a   Mao, Zhi ^a   Kang, Hongjun ^a   Hu, Jie ^a   Zhou, Feihu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Anticoagulation; Continuous renal replacement therapy; Heparin; Meta analysis; Regional citrate; Trial sequential analysis

Indexed keywords

CITRIC ACID; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MYELOPEROXIDASE; ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; ANTICOAGULATION; ARTICLE; BLEEDING; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DILUTION; DRUG EFFICACY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOCALCEMIA; META ANALYSIS; METABOLIC ALKALOSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SEQUENTIAL ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS; ADULT; CHINA; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; CHINA; CITRIC ACID; HEPARIN; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

EID: 85008627058     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/S13054-016-1299-0     Document Type: Article

References (44)

1. Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care. 2007;11(4):218.
2. Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol. 2011;7(9):499-508.
3. Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy-heparin or citrate? Crit Care. 2011;15(1):202.
4. Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med. 1983;308(5):258-61.
5. Section 5: Dialysis Interventions for Treatment of AKI. Kidney Int Suppl (2011). 2012;2(1):89-115. PMID:25018921 [PubMed] PMCID:PMC4089702. http://dx.doi.org/10.1038/kisup.2011.35
6. Balogun RA, Turgut F, Caldwell S, Abdel-Rahman EM. Regional citrate anticoagulation in critically ill patients with liver and kidney failure. J Nephrol. 2012;25(1):113-9.
7. Lanckohr C, Hahnenkamp K, Boschin M. Continuous renal replacement therapy with regional citrate anticoagulation: do we really know the details? Curr Opin Anaesthesiol. 2013;26(4):428-37.
8. Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a metaanalysis of randomized controlled trials. Am J Kidney Dis. 2012;59(6):810-8.
9. Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med. 2012;38(1):20-8.
10. Liao YJ, Zhang L, Zeng XX, Fu P. Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy. Chin Med J (Engl). 2013;126(7):1344-9.
11. Stucker F, Ponte B, Tataw J, Martin PY, Wozniak H, Pugin J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care. 2015;19:91.
12. Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med. 2015;43(8):1622-9.
13. Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care. 2014;18(4):472.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-41.
15. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380-2.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
17. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
18. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
19. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64-75.
20. Higgins JP, Whitehead A, Simmonds M. Sequential methods for randomeffects meta-analysis. Stat Med. 2011;30(9):903-21.
21. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009;38(1):276-86.
22. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009;9:86.
23. Thorlund K EJ, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). In Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark; 2011: p.1-115. Available from www.ctu.dk/tsa.
24. Betjes MG, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol. 2007;20(5):602-8.
25. Brain MJ, Roodenburg OS, Adams N, McCracken P, Hockings L, Musgrave S, et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Crit Care Resusc. 2014;16(2):131-7.
26. Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs. 2007;30(4):301-7.
27. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30(2):260-5.
28. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37(2):545-52.
29. Lin X, Qin Z, Chen L, Bu H. The comparing of anticoagulation with sodium citrate or heparin in continuous venovenous hemodiafiltration. Chin J Pract Intern Med. 2007;S1:194-6.
30. Cui W, Deng X, Lv S, Hu Q, Zhang K. The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. J Qiqihar Univ Med. 2011;12:1884-6.
31. Yang S, Deng Q, Li B, Xiao Y. Comparison of anticoagulation using regional heparin, citrate and low molecular weight heparins forcontinuous renal replacement therapy in critically ill patients. J China-Japan Friendship Hosp. 2014;04:208-11.
32. Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial. 2011;15(6):556-64.
33. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant. 2011;26(1):232-9.
34. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67(6):2361-7.
35. Cohen JF, Korevaar DA, Wang J, Spijker R, Bossuyt PM. Should we search Chinese biomedical databases when performing systematic reviews? Syst Rev. 2015;4:23.
36. Baldwin I. Factors affecting circuit patency and filter 'life'. Contrib Nephrol. 2007;156:178-84.
37. Wu B, Zhang K, Xu B, Ji D, Liu Z, Gong D. Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purif. 2015;39(4):306-12.
38. Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care. 2015;19:349.
39. Nurmohamed SA, Jallah BP, Vervloet MG, Yldirim G, Ter Wee PM, Groeneveld AB. Continuous venovenous haemofiltration with citratebuffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study. BMC Nephrol. 2013;14:89.
40. Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004;97(4):c131-136.
41. Park JS, Kim GH, Kang CM, Lee CH. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med. 2011;26(1):68-75.
42. Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Crit Care. 2014;18(2):R78.
43. Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol. 2014;15:19.
44. Feltes CM, Van Eyk J, Rabb H. Distant-organ changes after acute kidney injury. Nephron Physiol. 2008;109(4):80-4.